No Data
No Data
Beijing Chieftain Control Engineering Technology: Half-year report for the year 2024.
Beijing Chieftain Control Engineering Technology: Summary of Half-Year Report in 2024.
Beijing Chieftain Control Engineering Technology (300430.SZ) has not yet involved in business related to nuclear fuel component equipment.
Beijing Chieftain Control Engineering Technology (300430.SZ) stated on the investor interaction platform on July 26 that the company has not yet been involved in the business of nuclear fuel components and equipment.
Beijing Chieftain Control Engineering Technology (300430.SZ): There is no risk of mid-term performance collapse or being classified as Special Treat (ST).
On July 19th, Ge Longhui reported that Beijing Chieftain Control Engineering Technology (300430.SZ) stated on the investor interaction platform that the company is currently operating normally with a stable financial situation, and there is no risk of a mid-term performance slump or special treatment. Secondly, there is a question about accounts receivable. The company implements a development strategy of "one body, two wings, dual-wheel drive", with the pharmaceutical and biotechnology intelligent manufacturing business and rehabilitation medical device business as the company's two major business sectors. In the field of pharmaceutical and biotechnology intelligent manufacturing, the company mainly provides personalized overall solutions for pharmaceutical and biotechnology manufacturing enterprises, which belong to the engineering project business. The project implementation cycle is long, and during the project implementation process, downstream...
Beijing Chieftain Control Engineering Technology (stock code: 300430.SZ) is currently committed to combining brain-computer interface technology with existing rehabilitation products in order to achieve product upgrades.
On July 15th, Grillon announced on the Investor Relations Platform that it has partnered with Tsinghua University in the field of brain-computer interface, which is currently divided into invasive and non-invasive directions. In the field of non-invasive brain-computer interface, the company is currently committed to integrating brain-computer interface technology with existing rehabilitation products to upgrade products. On July 10, 2024, the company completed the release of three prototypes, and will gradually promote product certification in the future. At the same time, the company is also actively promoting intellectual property applications and joint project applications. In the field of invasive brain-computer interface, in May 2024, the company...
Beijing Chieftain Control Engineering Technology (stock code 300430.SZ): the current operation of the company is normal, and there is no risk of performance explosion or being labeled as special treatment.
On July 15th, Gelonhui reported that Beijing Chieftain Control Engineering Technology (stock code 300430.SZ) stated on the investor interaction platform that the company's operation is normal and there is no risk of performance breakdown or being given a special treatment (ST). As of now, the proportion of pledged shares held by the controlling shareholder and the consistent actor is 36.28%, with a relatively low pledge ratio and low liquidation price, and there is no risk of forced liquidation of the pledged shares.
No Data
No Data